<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomark Res</journal-id><journal-id journal-id-type="iso-abbrev">Biomark Res</journal-id><journal-title-group><journal-title>Biomarker Research</journal-title></journal-title-group><issn pub-type="epub">2050-7771</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40188348</article-id><article-id pub-id-type="pmc">PMC11972517</article-id>
<article-id pub-id-type="publisher-id">770</article-id><article-id pub-id-type="doi">10.1186/s40364-025-00770-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Development and validation of a predictive model based upon extracellular vesicle-derived transposable elements for non-invasive detection of pancreatic adenocarcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Liang</surname><given-names>Yueting</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Sui</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Shuai</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Haoxin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Wenyi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Minqi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Shaoran</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Weihu</given-names></name><address><email>wangweihu88@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Teng</surname><given-names>Huajing</given-names></name><address><email>hjteng@bjmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00nyxxr91</institution-id><institution-id institution-id-type="GRID">grid.412474.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0027 0586</institution-id><institution>Department of Radiation Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), </institution><institution>Peking University Cancer Hospital &#x00026; Institute, </institution></institution-wrap>Beijing, 100142 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00nyxxr91</institution-id><institution-id institution-id-type="GRID">grid.412474.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0027 0586</institution-id><institution>Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), </institution><institution>Peking University Cancer Hospital &#x00026; Institute, </institution></institution-wrap>Beijing, 100142 China </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>13</volume><elocation-id>54</elocation-id><history><date date-type="received"><day>22</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Pancreatic adenocarcinoma (PAAD) is a highly lethal malignancy that leads to patients missing optimal treatment opportunities due to its atypical clinical symptoms and the lack of effective diagnostic biomarkers. To develop a biomarker panel based on extracellular vesicle-derived transposable elements (EV-TEs) for non-invasive detection of PAAD, we analyzed 6.75 Tbp sequencing data of 852 EV-derived transcriptomes from two cohorts, and identified 31 EV-TEs features as the biomarker panel using recursive feature elimination. Predictive model constructed using the Support Vector Machine (SVM) algorithm demonstrated excellent performance for PAAD detection in the training set (AUC: 0.90, 95% CI: 0.86&#x02013;0.93), the test set (AUC: 0.86, 95% CI: 0.79&#x02013;0.92) and the independent external validation cohort of blood EV-derived samples (AUC: 0.88, 95% CI: 0.84&#x02013;0.92). This study presents the first EV-TEs based predictive model for PAAD detection, showcasing the immense potential of these &#x02018;junk DNA&#x02019; as innovative diagnostic biomarker for cancers.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s40364-025-00770-6.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Diagnostic biomarker</kwd><kwd>Transposable element</kwd><kwd>Pancreatic adenocarcinoma</kwd><kwd>Extracellular vesicle</kwd></kwd-group><funding-group><award-group><funding-source><institution>Peking University Cancer Hospital Science Foundation (No. JC202402)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Beijing Hospitals Authority Clinical Medicine Development of special funding support (No. ZLRK202327)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Beijing Hospitals Authority&#x02019;s Ascent Plan (No. DFL20220902)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Capital's Funds for Health Improvement and Research (No. 2024-2-2156)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Beijing Natural Science Foundation (Z230007)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>National Natural Science Foundation of China (No. 32370684)</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Yumed Inc. and BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par2">
<bold>To the editor,</bold>
</p><p id="Par3">Pancreatic adenocarcinoma (PAAD) accounts for approximately 5% of all cancer deaths worldwide [<xref ref-type="bibr" rid="CR1">1</xref>], and about 90% of PAAD patients are diagnosed at advanced stages with 5-year survival below 13% [<xref ref-type="bibr" rid="CR2">2</xref>]. Currently, carbohydrate antigen 19-9 (CA19-9) is widely used as an auxiliary diagnostic biomarker for PAAD but exhibits limited specificity and sensitivity, underscoring the pressing need to search for novel biomarkers for early diagnosis of PAAD [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par4">Extracellular vesicles (EVs) can transmit biomolecules from parent cells and exhibit strong stability in bodily fluids [<xref ref-type="bibr" rid="CR4">4</xref>]. Their unique characteristics herald a promising non-invasive approach for early cancer detection [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Transposable elements (TEs), once considered &#x02018;junk DNA&#x02019;, are now recognized as pivotal player in cancer development, and they are enriched in cell-free transcriptomes and preferentially packaged in cancer-derived EVs [<xref ref-type="bibr" rid="CR7">7</xref>]. However, the potential of EV-derived TEs (EV-TEs) as non-invasive biomarkers for PAAD diagnosis remains unexamined. Here, we analyzed 6.75 terabases of transcriptome sequencing data and employed three machine learning algorithms to construct PAAD predictive models based on EV-TEs.</p><p id="Par5">A total of 284 PAAD patients, 100 patients with chronic pancreatitis (CP) and 117 healthy controls were included in the discovery cohort [<xref ref-type="bibr" rid="CR8">8</xref>]. Meanwhile, a dataset including 150 PAAD, 49 CP and 152 healthy samples was designated as the external validation cohort (Table <xref rid="MOESM1" ref-type="media">S1</xref>) [<xref ref-type="bibr" rid="CR9">9</xref>]. Altogether, 852 EV-derived transcriptomes were processed, and quantification for each TE were obtained (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A-C). To identify the optimal set of EV-TE features for predicting PAAD, we employed the recursive feature elimination method in the discovery cohort, and ultimately selected 31 features as our EV-TEs biomarker panel (Fig.<xref rid="MOESM1" ref-type="media">S1</xref>A). Of the features, some were reported to be activated in cancers. For example, HERV1_I&#x02009;&#x02212;&#x02009;int has been significantly activated in colon adenocarcinoma [<xref ref-type="bibr" rid="CR10">10</xref>], and upregulated expression of LTR48B have been reported in multiple tumor types [<xref ref-type="bibr" rid="CR10">10</xref>]. A correlation analysis revealed that most of the 31 features exhibited weak to no correlation, indicating their independent contributions to the model (Fig.<xref rid="MOESM1" ref-type="media">S1</xref>B). Principal component analysis based on the biomarker panel effectively distinguishes PAAD from CP and healthy individuals (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>D). We then evaluated the predictive performance of the EV-TEs biomarker panel using three algorithms. Initially, we randomly split the discovery cohort into training (70%) and test (30%) sets. We then conducted a comparative analysis of clinical characteristics between PAAD and control (CP patients and healthy individuals) groups in different set (Table&#x000a0;S<xref rid="MOESM1" ref-type="media">2</xref>-<xref rid="MOESM1" ref-type="media">S5</xref>). Among the algorithms, the Support Vector Machine (SVM) model excelled, achieving an average area under the curve (AUC) of 0.90 and a Kappa coefficient of 0.66 in the training cohort (Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>E-F and <xref rid="Fig2" ref-type="fig">2</xref>A; Table&#x000a0;S<xref rid="MOESM1" ref-type="media">6</xref>). In the test set, the SVM model also demonstrated promising performance, with an average AUC of 0.86 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>D; Table&#x000a0;S<xref rid="MOESM1" ref-type="media">7</xref>). Binary classifications were then conducted leveraging its prediction strength, and the result further substantiated the SVM model&#x02019;s robust ability to distinguish PAAD from CP and healthy controls (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B, E,H). The training set confusion matrix revealed that 32 of 39 PAAD patients (82.1%) were accurately classified as true positives, and 30 of 31 healthy individuals (96.8%) were correctly identified as true negatives (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C). Similarly, in the test set, the model successfully classified 70 of 85 PAAD patients (82.4%) as true positives and accurately identified 55 of 66 healthy individuals (83.3%) as true negatives (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>F). These findings underscore the potential of SVM modeling for diagnosis in PAAD.</p><p id="Par6">
<fig id="Fig1"><label>Fig. 1</label><caption><p>The profile of plasma extracellular vesicle-derived transposable elements (EV-TEs) differs between PAAD, CP patients and healthy individuals. <bold>A</bold> Workflow of the study design for the identification of a plasma EV-derived TE panel as a biomarker for the diagnosis of PAAD patients. <bold>B</bold> Expression level of different types of repetitive sequences in PAAD patients versus CP and healthy control samples. <bold>C</bold> Given the lack of expression of certain TEs in the majority of samples, we performed filtering, and the remaining TEs (620) types exhibited a wide range of diversity. <bold>D</bold> Principal component analysis of PAAD, CP patients and healthy individuals based on the expression of 31 candidate EV-TEs. <bold>E</bold> Area under curve (AUC) performance for each machine learning model based on EV-TEs biomarker panel. <bold>F</bold> Kappa consistency value for each machine learning model based on the EV-TEs biomarker panel. PAAD, pancreatic adenocarcinoma; CP, chronic pancreatitis; DNA, DNA transposons; LINE, long interspersed nuclear elements; LTR, long terminal repeat; SINE, short interspersed nuclear elements; SAT, satellite sequence; CPM, counts per million; SVM, support vector machine. EM, Expectation-maximization algorithm</p></caption><graphic xlink:href="40364_2025_770_Fig1_HTML" id="d33e324"/></fig>
</p><p id="Par7">
<fig id="Fig2"><label>Fig. 2</label><caption><p>The diagnostic efficiency of plasma extracellular vesicle-derived transposable elements (EV-TEs) biomarker panel in detecting PAAD. <bold>A-I</bold> Receiver operating characteristic curve (ROC), binary classifications waterfall plot, and confusion matrix for EV-TEs panel for PAAD diagnosis in the training, test and external validation set. PAAD, pancreatic adenocarcinoma; TP, true-positive; FP, false-positive; TN, true-negative; FN, false-negative</p></caption><graphic xlink:href="40364_2025_770_Fig2_HTML" id="d33e339"/></fig>
</p><p id="Par8">To verify the reliability of the model, we conducted an external validation using an independent cohort. ROC analysis robustly demonstrated that it could distinguish PAAD from CP and healthy controls with an AUC value of 0.88 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>G). Consistent with these results, the confusion matrix for the validation set also showed that the model successfully classified 125 of 150 PAAD patients (83.3%) as true positives and accurately identified 166 of 201 healthy individuals (82.6%) as true negatives (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>I). CA19-9, the clinically widely-used diagnostic biomarker for PAAD, exhibits limited sensitivity (73.4&#x02013;77.4%) and specificity (75.4&#x02013;79.7%) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The findings above strengthened the potential of our EV-TEs panel as a non-invasive diagnostic tool for PAAD detection (Table&#x000a0;S<xref rid="MOESM1" ref-type="media">7</xref>), although we haven&#x02019;t compared its performance with that based on CA19-9 of the same cohort.</p><p id="Par9">Despite its achievements, the study faces key challenges. Age distributions differed between groups, with the PAAD group being older than the control group. Although this mirrors clinical observations [<xref ref-type="bibr" rid="CR12">12</xref>], we cannot exclude the confounding effect of age on the performance of our established prediction model. Furthermore, the absence of staging data for each patient hampers the interpretation of the biological significance of our panel in the detection of early stage PAAD patients. Thus, further validation in large-scale, multicenter trials is needed to fully evaluate the performance of the panel for early diagnosis of PAAD.</p><sec id="Sec2" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40364_2025_770_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Yueting Liang, Xin Sui and Shuai Li contributed equally to this work.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>H.T. and W.W. conceived and supervised the study. Y.L., X.S., S.L., W.J., M.J., and S.J. contributed to sample collection and collection of clinical information. Y.L., X.S., S.L., and H.P. contributed to data processing and integrative analyses. Y.L., X.S., W.W., and H.T. wrote the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the Beijing Natural Science Foundation (Z230007), National Natural Science Foundation of China (No. 32370684), Beijing Hospitals Authority Clinical Medicine Development of special funding support (No. ZLRK202327), Peking University Cancer Hospital Science Foundation (No. JC202402), Beijing Hospitals Authority&#x02019;s Ascent Plan (No. DFL20220902) and Capital&#x02019;s Funds for Health Improvement and Research (No. 2024-2-2156).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data and materials can be available from the corresponding authors, who can be contacted on the email address.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par10">This study was approved by the Ethics Committee of Peking University Cancer Hospital.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par11">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par12">The authors declare no competing interests.</p></notes><notes id="FPar4"><title>Abbreviations</title><p id="Par13">PAAD Pancreatic adenocarcinoma.</p><p id="Par14">CP Chronic pancreatitis.</p><p id="Par15">CA 19-9 Carbohydrate antigen 19-9.</p><p id="Par16">EV-TEs Extracellular vesicle-derived transposable elements.</p><p id="Par17">EVs Extracellular vesicles.</p><p id="Par18">TEs Transposable elements.</p><p id="Par19">SATs Satellite sequences.</p><p id="Par20">LTRs Long terminal repeats.</p><p id="Par21">LINEs Long interspersed nuclear elements.</p><p id="Par22">SINEs Short interspersed nuclear elements.</p><p id="Par23">AUC Area under the curve.</p><p id="Par24">LR Logistic Regression.</p><p id="Par25">RF Random Forest.</p><p id="Par26">SVM Support Vector Machine.</p></notes><notes id="FPar5"><title>Supplementary Information</title><p id="Par27">The online version contains supplementary Materials and Method, Supplementary Figures and Tables.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Sung</surname><given-names>H</given-names></name><etal/></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>Ca Cancer J Clin</source><year>2024</year><volume>74</volume><issue>3</issue><fpage>229</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 2024;74(3):229&#x02013;63.<pub-id pub-id-type="pmid">38572751</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Giaquinto</surname><given-names>AN</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2024</article-title><source>Ca Cancer J Clin</source><year>2024</year><volume>74</volume><issue>1</issue><fpage>12</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.3322/caac.21820</pub-id><pub-id pub-id-type="pmid">38230766</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. Ca Cancer J Clin. 2024;74(1):12&#x02013;49.<pub-id pub-id-type="pmid">38230766</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis</article-title><source>Int J Clin Exp Med</source><year>2015</year><volume>8</volume><issue>7</issue><fpage>11683</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">26380005</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Zhang Y, Yang J, Li H, Wu Y, Zhang H, Chen W. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. Int J Clin Exp Med. 2015;8(7):11683&#x02013;91.<pub-id pub-id-type="pmid">26380005</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>van Niel</surname><given-names>G</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>G</given-names></name><name><surname>Raposo</surname><given-names>G</given-names></name></person-group><article-title>Shedding light on the cell biology of extracellular vesicles</article-title><source>Nat Rev Mol Cell Biol</source><year>2018</year><volume>19</volume><issue>4</issue><fpage>213</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1038/nrm.2017.125</pub-id><pub-id pub-id-type="pmid">29339798</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">van Niel G, D&#x02019;Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213&#x02013;28.<pub-id pub-id-type="pmid">29339798</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Allenson</surname><given-names>K</given-names></name><name><surname>Castillo</surname><given-names>J</given-names></name><name><surname>San Lucas</surname><given-names>FA</given-names></name><etal/></person-group><article-title>High prevalence of mutant KRAS in Circulating exosome-derived DNA from early-stage pancreatic cancer patients</article-title><source>Ann Oncol</source><year>2017</year><volume>28</volume><issue>4</issue><fpage>741</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdx004</pub-id><pub-id pub-id-type="pmid">28104621</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Allenson K, Castillo J, San Lucas FA, et al. High prevalence of mutant KRAS in Circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol. 2017;28(4):741&#x02013;7.<pub-id pub-id-type="pmid">28104621</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Li H, Chiang CL, Kwak KJ et al. Extracellular Vesicular Analysis of Glypican 1 mRNA and Protein for Pancreatic Cancer Diagnosis and Prognosis. <italic>Advanced Science (Weinheim, Baden-Wurttemberg, Germany)</italic>. 2024;11(11):e2306373.</mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Reggiardo RE, Maroli SV, Halasz H et al. Mutant KRAS regulates transposable element RNA and innate immunity via KRAB zinc-finger genes. Cell Rep. 2022;40(3).</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma</article-title><source>Gut</source><year>2020</year><volume>69</volume><issue>3</issue><fpage>540</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2019-318860</pub-id><pub-id pub-id-type="pmid">31562239</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Yu S, Li Y, Liao Z, et al. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma. Gut. 2020;69(3):540&#x02013;50.<pub-id pub-id-type="pmid">31562239</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Circular RNA landscape in extracellular vesicles from human biofluids</article-title><source>Genome Med</source><year>2024</year><volume>16</volume><issue>1</issue><fpage>126</fpage><pub-id pub-id-type="doi">10.1186/s13073-024-01400-w</pub-id><pub-id pub-id-type="pmid">39482783</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Zhao J, Li Q, Hu J, et al. Circular RNA landscape in extracellular vesicles from human biofluids. Genome Med. 2024;16(1):126.<pub-id pub-id-type="pmid">39482783</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>Y</given-names></name><name><surname>Rose</surname><given-names>CM</given-names></name><name><surname>Cass</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Transposable element expression in tumors is associated with immune infiltration and increased antigenicity</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>5228</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-13035-2</pub-id><pub-id pub-id-type="pmid">31745090</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Kong Y, Rose CM, Cass AA, et al. Transposable element expression in tumors is associated with immune infiltration and increased antigenicity. Nat Commun. 2019;10(1):5228.<pub-id pub-id-type="pmid">31745090</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Diagnostic value of CA 19-9 and carcinoembryonic antigen for pancreatic cancer: A Meta-Analysis</article-title><source>Gastroenterol Res Pract</source><year>2018</year><volume>2018</volume><fpage>8704751</fpage><pub-id pub-id-type="doi">10.1155/2018/8704751</pub-id><pub-id pub-id-type="pmid">30584422</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Xing H, Wang J, Wang Y, et al. Diagnostic value of CA 19-9 and carcinoembryonic antigen for pancreatic cancer: A Meta-Analysis. Gastroenterol Res Pract. 2018;2018:8704751.<pub-id pub-id-type="pmid">30584422</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkeg&#x000e5;rd</surname><given-names>J</given-names></name><name><surname>Mortensen</surname><given-names>FV</given-names></name><name><surname>Cronin-Fenton</surname><given-names>D</given-names></name></person-group><article-title>Chronic pancreatitis and pancreatic cancer risk: A systematic review and Meta-analysis</article-title><source>Am J Gastroenterol</source><year>2017</year><volume>112</volume><issue>9</issue><fpage>1366</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1038/ajg.2017.218</pub-id><pub-id pub-id-type="pmid">28762376</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Kirkeg&#x000e5;rd J, Mortensen FV, Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: A systematic review and Meta-analysis. Am J Gastroenterol. 2017;112(9):1366&#x02013;72.<pub-id pub-id-type="pmid">28762376</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>